Status:
COMPLETED
Platelet Reactivity After CABG
Lead Sponsor:
University of Vermont
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Patients who have a heart attack are regularly treated with either clopidogrel or ticagrelor. In a large clinical trial, treatment with ticagrelor before coronary bypass surgery (CABG) was associated ...
Eligibility Criteria
Inclusion
- Acute coronary syndrome, CABG, within 48 hours of last dose of clopidogrel or ticagrelor, treatment with aspirin
Exclusion
- Treatment with an antiplatelet agent other than aspirin, clopidogrel, or ticagrelor, Acute or chronic hematologic disorder including a preoperative Hgb less than 10 g/dl or platelet count less than 100,000/mm3, Moderate or severe renal insufficiency (glomerular filtration rate less than 60 ml/min), Active infection, Active malignancy, Unable/unwilling to provide informed consent
Key Trial Info
Start Date :
May 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01793597
Start Date
May 1 2013
End Date
September 1 2015
Last Update
September 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont Medical Center
Burlington, Vermont, United States, 05401